

Table of Contents

<i>Declaration</i>	i
<i>Preface</i>	ii
<i>Acknowledgements</i>	iv
<i>Dedication</i>	vi
List of Abbreviations	vii
List of Figures	x
List of Tables	xi
List of Schemes	xii
Table of Contents	xiii

CHAPTER-I

1. Introduction	1
1.1. Metabolic syndrome	1
1.2. Diabetes	1
1.2.1. Types of diabetes	2
1.2.1.1. Type 1 diabetes mellitus (T1DM)	3
1.2.1.2. Type 2 diabetes mellitus (T2DM)	4
1.2.1.3. Gestational diabetes mellitus (GDM)	4
1.3. Pathogenesis of T2DM	5
1.4. Current & Newer therapies for the treatment of T2DM	6
1.4.1. Current therapies for the treatment of T2DM	6
1.4.1.1. Injectable therapies for the treatment of T2DM	6
1.4.1.2. Oral antidiabetic agents for the treatment of T2DM	9
1.4.2. Newer therapies for the treatment of T2DM	12
1.5. Introduction to Dipeptidyl Peptidase IV (DPP-IV) inhibitors	18

1.5.1.	DPP-IV and their importance	18
1.5.2.	Dipeptidyl peptidase family	20
1.5.3.	Role of DPP-IV in metabolic diseases	22
1.6.	Crystal structure of DPP-IV	24
1.7.	Molecular recognition of ligands in DPP-IV	28
1.8.	Mechanism of action of DPP-IV inhibitors	32
1.9.	Challenges in developing potent and selective DPP-IV inhibitors	32
1.10.	Overview on DPP-IV inhibitors under recent development	33
1.11.	Introduction to Cytochrome P450 (CYPs) and its importance	36
1.12.	Conclusion	37
CHAPTER-II		
2.	Design Strategy of DPP-IV inhibitors	38
2.1.	Orally active, potent and selective DPP-IV inhibitors	38
2.1.1.	Rational for designing cyanopyrrolidine containing peptidomimetic based DPP- IV inhibitors. (First series)	41
2.1.2.	Rational for designing peptidomimetic based DPP-IV inhibitors, devoid of CYP liabilities. (Second series)	42
2.1.3.	Rational for designing of aminomethylpiperidone based DPP-IV inhibitors. (Third series)	44
2.1.4.	Conclusion	46
CHAPTER-III		
3.	Results and discussion	47
3.1.	Cyanopyrrolidine containing peptidomimetic based DPP-IV inhibitors (First series)	48
3.1.1.	Chemistry	48

3.1.2.	<i>In vitro</i> DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR)	52
3.1.3.	<i>In vivo</i> antidiabetic activity of selected compounds (17c and 17d)	56
3.1.4.	Pharmacokinetic (PK) studies of selected compounds (17c and 17d)	57
3.1.5.	Molecular docking study of peptidomimetic 17c	58
3.1.6.	Conclusion	60
3.2.	Peptidomimetic based DPP-IV inhibitors, devoid of CYP liabilities (Second series)	60
3.2.1.	Chemistry	60
3.2.2.	<i>In vitro</i> DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR)	67
3.2.3.	<i>In vitro</i> CYP inhibition study of selected peptidomimetics	70
3.2.4.	Molecular docking study of lead peptidomimetic 34m	70
3.2.5.	Conclusion	72
3.3.	Aminomethylpiperidone based DPP-IV inhibitors (Third series)	73
3.3.1.	Chemistry	73
3.3.2.	<i>In vitro</i> DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR)	79
3.3.3.	<i>In vitro</i> CYP inhibition study of aminomethyl-piperidone 68v.	82
3.3.4.	<i>In vivo</i> antidiabetic activity of aminomethyl-piperidone 68v.	82
3.3.5.	Pharmacokinetic (PK) studies of aminomethyl-piperidone 68v	84
3.3.6.	Molecular docking study of aminomethyl-piperidone 68v	85
3.3.7.	Conclusion	86

CHAPTER-IV

4.	Overall summary and Future prospects	87
4.1.	Overall summary of current investigation	87
4.2.	Future Plan	90

CHAPTER-V

5.	Experimental	92
5.1.	Chemistry	92
5.1.1.	Materials and Methods	92
5.1.2.	Experimental Details	93
5.2.	Biology	202
5.2.1.	DPP-IV inhibitory activity and selectivity over other serine protease (<i>in vitro</i>)	202
5.2.2.	CYP inhibition study (<i>in vitro</i>)	203
5.2.3.	Pharmacodinemic study (Antidiabetic activity) (<i>in vivo</i>)	203
5.3.	Pharmacokinetic study (PK study)	204
5.4.	Docking study	204
6.	Spectral Data	205
	(ESI-MS, HPLC, ¹ H-NMR & ¹³ C-NMR of representative compounds)	
7.	Referances	293
8.	Publications	309
9.	Vitae	328